Oral roflumilast for moderate to severe atopic dermatitis in people 12 and older
Tests oral roflumilast in people with moderate to severe atopic dermatitis.
Plain-language title generated from the registry record
Registry title: Evaluation of Efficacy and Safety of Oral Roflumilast for Treatment of Moderate to Severe Atopic Dermatitis in Patients Aged 12 Years and Older: A Pilot Study
Key facts
- Where
- Al Mansurah, EgyptSee the site
- Phase
- Phase 2
Where in Egypt
- Mansoura university HospitalAl Mansurah, EgyptTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Nora Mohamed Abdelrazik
- Trial code
- NCT07297602
- Record updated
- 30 December 2025
- Original description
This is a 12-week, single-arm, open-label pilot study to assess the safety and preliminary efficacy of oral roflumilast in patients aged 12 years and older with moderate-to-severe atopic dermatitis All participants, both male and female, will receive oral roflumilast starting at 250 mcg once daily for 10 days, followed by 500 mcg once daily for the remainder of the study. The primary outcome is the mean change in SCORAD (Scoring Atopic Dermatitis) score from baseline to Week 12. Secondary outcome include safety assessments, including treatment-emergent adverse events, serious adverse events, and laboratory abnormalities. Male and female participants will be analyzed as subgroups to explore potential differences in response or safety.Read full original descriptionShow less
Evaluation of Efficacy and Safety of Oral Roflumilast in Treatment of Moderate to Severe Atopic Dermatitis: a Pilot Study
This is a 12-week, single-arm, open-label pilot study to assess the safety and preliminary efficacy of oral roflumilast in patients aged 12 years and older with moderate-to-severe atopic dermatitis All participants, both male and female, will receive oral roflumilast starting at 250 mcg once daily for 10 days, followed by 500 mcg once daily for the remainder of the study. The primary outcome is the mean change in SCORAD (Scoring Atopic Dermatitis) score from baseline to Week 12. Secondary outcome include safety assessments, including treatment-emergent adverse events, serious adverse events, and laboratory abnormalities. Male and female participants will be analyzed as subgroups to explore potential differences in response or safety.
Inclusion: AD patients ≥ 12 years in whom systemic therapy is indicated; Patients who don't use other systemic therapy for AD in the last 2 months (or naïve who didn't use any systemic therapy before); Safe contraception during the study.
Exclusion: Other concomitant AD systemic treatments such as cyclosporins and biologics; Previous systemic treatment of AD in the last 2 months; Patients receiving inducers or inhibitors of cytochromes CYP3A4 and CYP1A; Other systemic diseases other than COPD, especially hepatic impairment; Hypersensitivity to the active substance of roflumilast or to any of its excipients; Age <12 years; Pregnant or lactating women, as well as women of childbearing potential not using an effective method of contraception; The use of contraception with gestodene and ethinylestradiol; Unreliable patients.